Page 104 - Genentech News Today

The road to effective cancer vaccines has been long and difficult. Although initial attempts to use a vaccine to treat cancer date back to the 1910s, the first effective therapeutic vaccine would not emerge until about a century later, when Sipuleuce

CAMBRIDGE, Mass., Sept. 06, 2023 -- Biogen Inc. announced the appointment of Jane Grogan, Ph.D., as Executive Vice President, Head of Research effective 2 October 2023. Dr. Grogan will be a member...

The Boston-based biotech will work on new "small molecule" drugs to combat cancer and other ailments.

LEXINGTON, Mass., Sept. 6, 2023 /PRNewswire/ -- Curis, Inc. , a biotechnology company focused on the development of emavusertib, an orally available small molecule IRAK4 inhibitor for the treatment...

Lineage Cell Therapeutics, Inc. ; class=js-l-obf link link--blue

Age-related macular degeneration can now be treated but many still avoid annual eye exams critical for detection.

Although antiretroviral therapies are the standard of care treatment for those with HIV, the drugs cannot target latent infections; however, venetoclax, a blood cancer treatment, shows promise.

BioPharma

The FDA has accepted a biologics license application seeking the approval of crovalimab for use in patients with paroxysmal nocturnal hemoglobinuria.

Grogan joins Biogen following a decades-long career in biopharma, including leadership roles at Genentech and Graphite Bio.